Tysabri and Sinus bradycardia - a phase IV clinical study of FDA data

Summary:

Sinus bradycardia is reported as a side effect among people who take Tysabri (natalizumab), especially for people who are female, 50-59 old, have been taking the drug for 6 - 12 months also take Baclofen, and have Iron deficiency anaemia.

The phase IV clinical study analyzes which people have Sinus bradycardia when taking Tysabri. It is created by eHealthMe based on reports of 220,870 people who have side effects when taking Tysabri from the FDA, and is updated regularly.

What is Tysabri?

Tysabri has active ingredients of natalizumab. It is often used in multiple sclerosis. eHealthMe is studying from 221,369 Tysabri users. Check the latest studies of Tysabri.

What is Sinus bradycardia?

Sinus bradycardia (an unusually slow heartbeat due to heart disease) is found to be associated with 905 drugs and 1,053 conditions by eHealthMe. Check the latest studies of Sinus bradycardia.

On Jul, 15, 2026

220,870 people reported to have side effects when taking Tysabri.
Among them, 20 people (0.01%) have Sinus bradycardia.

Among these 20 people:

How long have people been on Tysabri when they have Sinus bradycardia? *

What is the gender of people who have Sinus bradycardia when taking Tysabri? *

female: 75 %
male: 25 %

What is the age of people who have Sinus bradycardia when taking Tysabri? *

What are other drugs people take besides Tysabri? *

Furosemide: 5 people, 25.00%
Baclofen: 5 people, 25.00%
Synthroid: 4 people, 20.00%
Lexapro: 4 people, 20.00%
Albuterol Sulfate: 3 people, 15.00%
Cozaar: 3 people, 15.00%
Pravastatin Sodium: 3 people, 15.00%
Nitroglycerin: 3 people, 15.00%
Allopurinol: 3 people, 15.00%
Prochlorperazine Maleate: 3 people, 15.00%

What are other side effects people have besides Sinus bradycardia? *

Acute Kidney Failure: 4 people, 20.00%
Oedema Peripheral (superficial swelling): 4 people, 20.00%
Dyspnea (difficult or laboured breathing): 4 people, 20.00%
Haematocrit Decreased: 3 people, 15.00%
Atrioventricular Block First Degree (heart block first degree): 3 people, 15.00%
Haemoglobin Decreased: 3 people, 15.00%
Diabetic Nephropathy (diabetic kidney disease): 3 people, 15.00%
Brain Natriuretic Peptide Increased: 3 people, 15.00%
Type 2 Diabetes: 3 people, 15.00%
Intervertebral Disc Degeneration (spinal disc degeneration): 2 people, 10.00%

What are the existing conditions these people have? *

Iron Deficiency Anaemia: 5 people, 25.00%
Paraesthesia (sensation of tingling, tickling, prickling, pricking, or burning of a person's skin with no apparent long-term physical effect): 4 people, 20.00%
Muscle Spasticity (tight or stiff muscles and an inability to control those muscles): 4 people, 20.00%
Multiple Myeloma (cancer of the plasma cells): 2 people, 10.00%
Wheezing (a high-pitched whistling sound made while you breath): 1 person, 5.00%
Sleep Disorder: 1 person, 5.00%
Sedation: 1 person, 5.00%
Progressive Relapsing Multiple Sclerosis (chronic autoimmune disease of the central nervous system in which gradual destruction of myelin occurs in patches throughout the brain or spinal cord or both): 1 person, 5.00%
Pain: 1 person, 5.00%
Osteoporosis (bones weak and more likely to break): 1 person, 5.00%

* Approximation only. Some reports may have incomplete information.

Do you take Tysabri and have Sinus bradycardia?

- Check whether Sinus bradycardia is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Tysabri:

Tysabri (221,369 reports)

Browse all side effects of Tysabri:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Sinus bradycardia:

Sinus bradycardia (905 drugs)

Browse all the conditions that are associated with Sinus bradycardia:

Sinus bradycardia (1,053 conditions)

Related publications that referenced our studies

Yaylaci S, Kocayigit I, Genc A, Tamer A, Gunduz H, "Sinus bradycardia caused by flurbiprofen intoxication", Nigerian Journal of Cardiology, 2015 Jan .
Yaylaci S, Kocayigit I, Genc A, Tamer A, Gunduz H, "Sinus bradycardia caused by flurbiprofen intoxication", Nigerian Journal of Cardiology, 2015 Jan .

How the study uses the data?

The study uses data from the FDA. It is based on natalizumab (the active ingredients of Tysabri) and Tysabri (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.